A detailed history of Glen Eagle Advisors, LLC transactions in Pfizer Inc stock. As of the latest transaction made, Glen Eagle Advisors, LLC holds 26,968 shares of PFE stock, worth $740,541. This represents 0.14% of its overall portfolio holdings.

Number of Shares
26,968
Previous 8,522 216.45%
Holding current value
$740,541
Previous $302 Million 149.49%
% of portfolio
0.14%
Previous 0.25%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$25.26 - $29.6 $465,945 - $546,001
18,446 Added 216.45%
26,968 $755 Million
Q1 2024

Jul 03, 2024

BUY
$25.89 - $29.73 $982,447 - $1.13 Million
37,947 New
37,947 $1.05 Billion
Q4 2023

Aug 13, 2024

SELL
$26.13 - $33.94 $203,213 - $263,951
-7,777 Reduced 15.25%
43,207 $1.24 Billion
Q3 2023

Aug 13, 2024

SELL
$32.09 - $37.51 $8,760 - $10,240
-273 Reduced 0.53%
50,984 $1.69 Billion
Q2 2023

Aug 13, 2024

BUY
$36.12 - $41.79 $187,751 - $217,224
5,198 Added 11.29%
51,257 $1.88 Billion
Q1 2023

Aug 13, 2024

BUY
$39.39 - $51.28 $100,326 - $130,610
2,547 Added 5.85%
46,059 $1.88 Billion
Q4 2022

Aug 13, 2024

SELL
$41.75 - $54.5 $18,411 - $24,034
-441 Reduced 1.0%
43,512 $2.23 Billion
Q3 2022

Aug 13, 2024

SELL
$43.76 - $53.42 $377,823 - $461,228
-8,634 Reduced 16.42%
43,953 $1.92 Billion
Q2 2022

Aug 13, 2024

BUY
$46.53 - $55.17 $256,566 - $304,207
5,514 Added 11.71%
52,587 $2.76 Billion
Q1 2022

Aug 13, 2024

SELL
$45.75 - $56.69 $4,529 - $5,612
-99 Reduced 0.21%
47,073 $2.44 Billion
Q4 2021

Aug 13, 2024

SELL
$41.32 - $61.25 $67,806 - $100,511
-1,641 Reduced 3.36%
47,172 $2.79 Billion
Q3 2021

Aug 13, 2024

BUY
$39.25 - $50.42 $107,388 - $137,949
2,736 Added 5.94%
48,813 $2.1 Billion
Q2 2021

Aug 13, 2024

BUY
$35.91 - $40.68 $38,782 - $43,934
1,080 Added 2.4%
46,077 $1.8 Billion
Q1 2021

Aug 13, 2024

BUY
$33.49 - $37.77 $94,609 - $106,700
2,825 Added 6.7%
44,997 $1.64 Billion
Q4 2020

Aug 13, 2024

BUY
$33.47 - $42.56 $141,410 - $179,816
4,225 Added 11.13%
42,172 $1.55 Billion
Q3 2020

Aug 13, 2024

BUY
$31.75 - $37.25 $151,225 - $177,421
4,763 Added 12.91%
41,649 $1.53 Billion
Q2 2020

Aug 13, 2024

BUY
$30.12 - $36.54 $590,803 - $716,732
19,615 Added 113.57%
36,886 $1.21 Billion
Q1 2020

Aug 13, 2024

BUY
$27.03 - $38.62 $108,390 - $154,866
4,010 Added 30.24%
17,271 $564 Million
Q4 2019

Aug 13, 2024

BUY
$32.92 - $37.36 $74,925 - $85,031
2,276 Added 20.72%
13,261 $520 Million
Q3 2019

Aug 13, 2024

BUY
$32.49 - $42.13 $6,270 - $8,131
193 Added 1.79%
10,985 $395 Million
Q2 2019

Aug 13, 2024

BUY
$36.98 - $41.52 $3,180 - $3,570
86 Added 0.8%
10,792 $468 Million
Q1 2019

Aug 13, 2024

SELL
$37.5 - $41.2 $1.02 Million - $1.12 Million
-27,241 Reduced 71.79%
10,706 $455 Million
Q4 2018

Aug 13, 2024

BUY
$38.47 - $43.86 $7,001 - $7,982
182 Added 1.84%
10,085 $440 Million
Q3 2018

Aug 13, 2024

SELL
$34.47 - $41.81 $5,170 - $6,271
-150 Reduced 1.49%
9,903 $436 Million
Q2 2018

Aug 13, 2024

SELL
$32.98 - $35.16 $6.61 Million - $7.05 Million
-200,479 Reduced 95.22%
10,053 $365 Million
Q1 2018

Aug 14, 2024

SELL
$31.91 - $37.02 $938,951 - $1.09 Million
-29,425 Reduced 77.54%
8,522 $302 Million
Q1 2018

Aug 13, 2024

BUY
$31.91 - $37.02 $6.47 Million - $7.51 Million
202,817 Added 2628.87%
210,532 $302 Million
Q4 2017

Aug 13, 2024

BUY
$33.26 - $35.29 $13,802 - $14,645
415 Added 5.68%
7,715 $279 Million
Q3 2017

Aug 13, 2024

SELL
$31.0 - $34.15 $950,057 - $1.05 Million
-30,647 Reduced 80.76%
7,300 $261 Million
Q2 2017

Aug 12, 2024

BUY
N/A
180 Added 1.95%
9,419 $316 Million
Q1 2017

Aug 12, 2024

SELL
N/A
-222 Reduced 2.35%
9,239 $317 Million
Q4 2016

Aug 12, 2024

SELL
N/A
-28,486
9,461 $307 Million

Others Institutions Holding PFE

About PFIZER INC


  • Ticker PFE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 5,612,349,952
  • Market Cap $154B
  • Description
  • Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...
More about PFE
Track This Portfolio

Track Glen Eagle Advisors, LLC Portfolio

Follow Glen Eagle Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Glen Eagle Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Glen Eagle Advisors, LLC with notifications on news.